Literature DB >> 15687223

Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure.

B J Eickholt1, G J Towers, W J Ryves, D Eikel, K Adley, L M J Ylinen, N H Chadborn, A J Harwood, H Nau, R S B Williams.   

Abstract

Inositol-1,4,5-trisphosphate (InsP3) depletion has been implicated in the therapeutic action of bipolar disorder drugs, including valproic acid (VPA). It is not currently known whether the effect of VPA on InsP3 depletion is related to the deleterious effects of teratogenicity or elevated viral replication, or if it occurs via putative inhibitory effects on glycogen synthase kinase-3beta (GSK-3beta). In addition, the structural requirements of VPA-related compounds to cause InsP3 depletion are unknown. In the current study, we selected a set of 10 VPA congeners to examine their effects on InsP3 depletion, in vivo teratogenic potency, HIV replication, and GSK-3beta activity in vitro. We found four compounds that function to deplete InsP3 in the model eukaryote Dictyostelium discoideum, and these drugs all cause growth-cone enlargement in mammalian primary neurons, consistent with the effect of InsP3 depletion. No relationship was found between InsP3 depletion and teratogenic or elevated viral replication effects, and none of the VPA congeners were found to affect GSK-3beta activity. Structural requirements of VPA congers to maintain InsP3 depletion efficacy greater than that of lithium are a carboxylic-acid function without dependence on side-chain length, branching, or saturation. Noteworthy is the enantiomeric differentiation if a chiral center exists, suggesting that InsP3 depletion is mediated by a stereoselective mode of action. Thus, the effect of InsP3 depletion can be separated from that of teratogenic potency and elevated viral replication effect. We have used this to identify two VPA derivatives that share the common InsP3-depleting action of VPA, lithium and carbamazepine, but do not show the side effects of VPA, thus providing promising novel candidates for bipolar disorder treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15687223      PMCID: PMC1360212          DOI: 10.1124/mol.104.009308

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  39 in total

1.  On the development of alternative antiepileptic drugs. Lack of enantioselectivity of the anticonvulsant activity, in contrast to teratogenicity, of 2-n-propyl-4-pentenoic acid and 2-n-propyl-4-pentynoic acid, analogues of the anticonvulsant drug valproic acid.

Authors:  R S Hauck; H Nau; M M Elmazar
Journal:  Naturwissenschaften       Date:  1991-06

Review 2.  Neural and developmental actions of lithium: a unifying hypothesis.

Authors:  M J Berridge; C P Downes; M R Hanley
Journal:  Cell       Date:  1989-11-03       Impact factor: 41.582

3.  A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations.

Authors:  H Nau; R Zierer; H Spielmann; D Neubert; C Gansau
Journal:  Life Sci       Date:  1981-12-28       Impact factor: 5.037

4.  A molecular mechanism for the effect of lithium on development.

Authors:  P S Klein; D A Melton
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

5.  The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism.

Authors:  G R Granneman; S I Wang; J W Kesterson; J M Machinist
Journal:  Hepatology       Date:  1984 Nov-Dec       Impact factor: 17.425

6.  Increased human cytomegalovirus replication in fibroblasts after treatment with therapeutical plasma concentrations of valproic acid.

Authors:  Martin Michaelis; Nezira Köhler; Alexander Reinisch; Daniel Eikel; Ute Gravemann; Hans Wilhelm Doerr; Heinz Nau; Jindrich Cinatl
Journal:  Biochem Pharmacol       Date:  2004-08-01       Impact factor: 5.858

Review 7.  Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms.

Authors:  H Nau; R S Hauck; K Ehlers
Journal:  Pharmacol Toxicol       Date:  1991-11

8.  Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure.

Authors:  J D York; J W Ponder; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

9.  Chemical and kinetic mechanism of the inositol monophosphatase reaction and its inhibition by Li+.

Authors:  A P Leech; G R Baker; J K Shute; M A Cohen; D Gani
Journal:  Eur J Biochem       Date:  1993-03-15

10.  Effects of haloperidol, lithium, and valproate on phosphoinositide turnover in rat brain.

Authors:  R Li; L L Wing; R J Wyatt; D G Kirch
Journal:  Pharmacol Biochem Behav       Date:  1993-10       Impact factor: 3.533

View more
  29 in total

1.  Inositol synthesis regulates the activation of GSK-3α in neuronal cells.

Authors:  Cunqi Ye; Miriam L Greenberg
Journal:  J Neurochem       Date:  2014-11-17       Impact factor: 5.372

2.  Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction.

Authors:  Yan Leng; Zoya Marinova; Marcos A Reis-Fernandes; Heinz Nau; De-Maw Chuang
Journal:  Neurosci Lett       Date:  2010-04-13       Impact factor: 3.046

3.  Modulation of synaptic transmission and analysis of neuroprotective effects of valproic Acid and derivates in rat embryonic motoneurons.

Authors:  D Ragancokova; Y Song; H Nau; R Dengler; K Krampfl; S Petri
Journal:  Cell Mol Neurobiol       Date:  2010-04-27       Impact factor: 5.046

4.  Identifying an uptake mechanism for the antiepileptic and bipolar disorder treatment valproic acid using the simple biomedical model Dictyostelium.

Authors:  Nicole Terbach; Rishita Shah; Rachel Kelemen; Peter S Klein; Dmitri Gordienko; Nigel A Brown; Christopher J Wilkinson; Robin S B Williams
Journal:  J Cell Sci       Date:  2011-06-07       Impact factor: 5.285

5.  Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid.

Authors:  Xuehua Xu; Annette Müller-Taubenberger; Kathryn E Adley; Nadine Pawolleck; Vivian W Y Lee; Claudia Wiedemann; Talvinder S Sihra; Markus Maniak; Tian Jin; Robin S B Williams
Journal:  Eukaryot Cell       Date:  2007-04-13

6.  Genetic control of lithium sensitivity and regulation of inositol biosynthetic genes.

Authors:  Jason King; Melanie Keim; Regina Teo; Karin E Weening; Mridu Kapur; Karina McQuillan; Jonathan Ryves; Ben Rogers; Emma Dalton; Robin S B Williams; Adrian J Harwood
Journal:  PLoS One       Date:  2010-06-17       Impact factor: 3.240

Review 7.  GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder.

Authors:  Michael K Rowe; Charlotte Wiest; De-Maw Chuang
Journal:  Neurosci Biobehav Rev       Date:  2007-03-15       Impact factor: 8.989

8.  The transcriptional activator Ino2p dissociates from the yeast INM1 promoter in induction.

Authors:  Lingzhi Zhang; Jing Di
Journal:  DNA Cell Biol       Date:  2014-12       Impact factor: 3.311

Review 9.  Inositol depletion, GSK3 inhibition and bipolar disorder.

Authors:  Wenxi Yu; Miriam L Greenberg
Journal:  Future Neurol       Date:  2016-04-26

10.  Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition.

Authors:  Yan Leng; Min-Huei Liang; Ming Ren; Zoya Marinova; Peter Leeds; De-Maw Chuang
Journal:  J Neurosci       Date:  2008-03-05       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.